Please login to the form below

Not currently logged in
Email:
Password:

Keryx Biopharmaceuticals

This page shows the latest Keryx Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... Keryx Biopharmaceuticals' Fexeric has been approved in Europe as a treatment for controlling phosphorus levels in adults with chronic kidney disease.

Latest news

  • Aeterna Zentaris under the cosh as myeloma candidate fails

    That result prompted the US developer of the drug, Keryx Biopharmaceuticals, to return rights to Aeterna Zentaris, which is also exploring the activity of perifosine in renal cell carcinoma, non-small

  • Extending the arsenal

    Introducing perifosine. Perifosine is a small-molecule compound that was originally discovered by Zentaris (now AEterna Zentaris) and has since been licensed to Keryx Biopharmaceuticals in the US, Canada and Mexico,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics